Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials
CONCLUSIONS: The proposed methods comprehensively characterize the treatment effects on the entire clinical course of a hospitalized COVID-19 patient.PMID:38618926 | DOI:10.1177/17407745241238443 (Source: Clinical Trials)
Source: Clinical Trials - April 15, 2024 Category: Research Authors: Dan-Yu Lin Jianqiao Wang Yu Gu Donglin Zeng Source Type: research
Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials
CONCLUSIONS: The proposed methods comprehensively characterize the treatment effects on the entire clinical course of a hospitalized COVID-19 patient.PMID:38618926 | DOI:10.1177/17407745241238443 (Source: Clinical Trials)
Source: Clinical Trials - April 15, 2024 Category: Research Authors: Dan-Yu Lin Jianqiao Wang Yu Gu Donglin Zeng Source Type: research
Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials
CONCLUSIONS: The proposed methods comprehensively characterize the treatment effects on the entire clinical course of a hospitalized COVID-19 patient.PMID:38618926 | DOI:10.1177/17407745241238443 (Source: Clinical Trials)
Source: Clinical Trials - April 15, 2024 Category: Research Authors: Dan-Yu Lin Jianqiao Wang Yu Gu Donglin Zeng Source Type: research
Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials
CONCLUSIONS: The proposed methods comprehensively characterize the treatment effects on the entire clinical course of a hospitalized COVID-19 patient.PMID:38618926 | DOI:10.1177/17407745241238443 (Source: Clinical Trials)
Source: Clinical Trials - April 15, 2024 Category: Research Authors: Dan-Yu Lin Jianqiao Wang Yu Gu Donglin Zeng Source Type: research
REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program
ConclusionsVery high adherence rates independent of the PSP nursing service over 1 year of treatment indicate that IFN beta-1a sc is an easy-to-use and well-tolerated disease-modifying drug.Trial Registration NumberVfa.de: No. 892.https://www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-arzneimitteln/nisdb/nis-details/_892. (Source: Neurology and Therapy)
Source: Neurology and Therapy - March 26, 2024 Category: Neurology Source Type: research
Correction to: The impact of metformin use on the outcomes of relapse ‑remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open‑label randomized controlled trial
(Source: Journal of Neurology)
Source: Journal of Neurology - March 18, 2024 Category: Neurology Source Type: research
GSE247181 Novel Biomarkers and Interferon Signature in Secondary Progressive Multiple Sclerosis
Contributors : Avital Fogel ; Maya Olcer ; Aika Goel ; Xuan Feng ; Anthony T RederSeries Type : Expression profiling by arrayOrganism : Homo sapiensTranscriptome analysis of RNA samples from human PBMCs of IFN-beta-1a (Rebif) therapy in secondary progressive multiple sclerosis (SPMS) patients.Objective: Untreated multiple sclerosis is inflammatory, with decreased immune control and subnormal type I interferon (IFN) signaling. IFN- ß therapy corrects abnormal IFN-ß signaling, reduces inflammation on MRI, exacerbations, and disease worsening in relapsing-remitting MS (RRMS). For unclear reasons, secondary progressive M...
Source: GEO: Gene Expression Omnibus - March 7, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Author Correction: Utilization of peginterferon- β-1a in the real-world practice for relapsing-remitting multiple sclerosis
Conclusions section of the abstract, "SC PEG-IFN-β-1a and IFN- β-1a" is corrected to "PEG-IFN-β-1a and SC IFN-β-1a". • In the Population section, the study period "January 1st 2015 to December 31st 2019" was not reported; therefore, this specification has been added to the text. • The legend of Figure 1 was wrongly reported as the same as Table I. The correct title of Figure 1 is "Study flow diagram". • Under Tables I, II, and III, "interferon beta 1a IFN-β-1a" is corrected to "interferon beta 1a (IFN-β-1a)". • In Table III, "CS Glatiramer acetate" is corrected to "SC Glatiramer acetate". • In the Conclusio...
Source: Pharmacological Reviews - March 4, 2024 Category: Drugs & Pharmacology Authors: M Moccia L Santoni I Vaccari G Affinito D Caliendo F Rubba R Lanzillo M Triassi V Brescia Morra R Palladino Source Type: research
Author Correction: Utilization of peginterferon- β-1a in the real-world practice for relapsing-remitting multiple sclerosis
Conclusions section of the abstract, "SC PEG-IFN-β-1a and IFN- β-1a" is corrected to "PEG-IFN-β-1a and SC IFN-β-1a". • In the Population section, the study period "January 1st 2015 to December 31st 2019" was not reported; therefore, this specification has been added to the text. • The legend of Figure 1 was wrongly reported as the same as Table I. The correct title of Figure 1 is "Study flow diagram". • Under Tables I, II, and III, "interferon beta 1a IFN-β-1a" is corrected to "interferon beta 1a (IFN-β-1a)". • In Table III, "CS Glatiramer acetate" is corrected to "SC Glatiramer acetate". • In the Conclusio...
Source: European Review for Medical and Pharmacological Sciences - March 4, 2024 Category: Drugs & Pharmacology Authors: M Moccia L Santoni I Vaccari G Affinito D Caliendo F Rubba R Lanzillo M Triassi V Brescia Morra R Palladino Source Type: research
Author Correction: Utilization of peginterferon- β-1a in the real-world practice for relapsing-remitting multiple sclerosis
Conclusions section of the abstract, "SC PEG-IFN-β-1a and IFN- β-1a" is corrected to "PEG-IFN-β-1a and SC IFN-β-1a". • In the Population section, the study period "January 1st 2015 to December 31st 2019" was not reported; therefore, this specification has been added to the text. • The legend of Figure 1 was wrongly reported as the same as Table I. The correct title of Figure 1 is "Study flow diagram". • Under Tables I, II, and III, "interferon beta 1a IFN-β-1a" is corrected to "interferon beta 1a (IFN-β-1a)". • In Table III, "CS Glatiramer acetate" is corrected to "SC Glatiramer acetate". • In the Conclusio...
Source: Pharmacological Reviews - March 4, 2024 Category: Drugs & Pharmacology Authors: M Moccia L Santoni I Vaccari G Affinito D Caliendo F Rubba R Lanzillo M Triassi V Brescia Morra R Palladino Source Type: research
Author Correction: Utilization of peginterferon- β-1a in the real-world practice for relapsing-remitting multiple sclerosis
Conclusions section of the abstract, "SC PEG-IFN-β-1a and IFN- β-1a" is corrected to "PEG-IFN-β-1a and SC IFN-β-1a". • In the Population section, the study period "January 1st 2015 to December 31st 2019" was not reported; therefore, this specification has been added to the text. • The legend of Figure 1 was wrongly reported as the same as Table I. The correct title of Figure 1 is "Study flow diagram". • Under Tables I, II, and III, "interferon beta 1a IFN-β-1a" is corrected to "interferon beta 1a (IFN-β-1a)". • In Table III, "CS Glatiramer acetate" is corrected to "SC Glatiramer acetate". • In the Conclusio...
Source: European Review for Medical and Pharmacological Sciences - March 4, 2024 Category: Drugs & Pharmacology Authors: M Moccia L Santoni I Vaccari G Affinito D Caliendo F Rubba R Lanzillo M Triassi V Brescia Morra R Palladino Source Type: research
